Menu Login / Registration Search
CZ

CLIA Scl-70

Chemiluminescence kit for the detection of Scl-70 antibodies in human serum or plasma.

Available
Catalog Number: CL-Scl050
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Immunology & Autoimmune Diseases
Diagnostic panel: Rheumatic Diseases
CLIA Scl-70
  • Detection of anti-Scl-70 antibodies, IgG class
  • Evaluating patients with clinical signs and symptoms compatible with systemic sclerosis and positive test for antinuclear antibodies
  • Intended for human serum and plasma
  • A mixture of native and recombinant Scl-70antigens used

The Scl-70 antigen is a type I DNA topoisomerase. It has a native molecular weight of 100 kDa. The enzyme is degraded to a protein of 70 kDa and less. Anti-Scl-70 antibodies bind to a native form of the antigen as well as to proteolysis products with lower molecular weights.

Presence of Anti-Scl-70 antibodies is highly specific serological marker for diffuse form of systemic scleroderma. They are present in 20-40% of individuals with systemic scleroderma. They indicate worse disease prognosis, and higher probability of musculoskeletal system and organ affections (lung fibrosis, proteinuria, heart damage). Anti-Scl-70 antibodies are rarely present in localized form of scleroderma. The antibody level corresponds with the disease activity.

Antigen Used: A mixture of native and recombinant Scl-70 antigens.

Technical specifications

Technical data
References
Related Products
Downloads

Technical data

Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume10 µL
Measuring range3-320 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, AnchorĀ® Tips, Stackable cuvettes, Trigger solutions
Note

The kits are CE-IVD certified and intended for professional use.

References

References to CLIA Scl-70

  • Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma. 1986;94(2):132-8. doi: 10.1007/BF00286991. PMID: 2428564.
    See more on PubMed
  • Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997 Sep;103(3):242-8. doi: 10.1016/s0002-9343(97)00023-5. PMID: 9316557.
    See more on PubMed
  • Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80-93. doi: 10.1186/ar628. Epub 2003 Feb 12. PMID: 12718748; PMCID: PMC165038.
    See more on PubMed
  • Mecoli CA, Casciola-Rosen L. An update on autoantibodies in scleroderma. Curr Opin Rheumatol. 2018 Nov;30(6):548-553. doi: 10.1097/BOR.0000000000000550. PMID: 30148799; PMCID: PMC6546089.
    See more on PubMed
  • Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol. 2004 Nov;16(6):723-32. doi: 10.1097/01.bor.0000144760.37777.fa. PMID: 15577611.
    See more on PubMed

Downloads

Safety information

Declaration of conformity

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *
Up